# ViceBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vicebio

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.vicebio.com
- Total disclosed funding: $100M
- Latest round: Series B (Sep 23, 2024)
- Investors on record: 6

## About

ViceBio Limited is a biotechnology firm founded in 2019 with headquarters in London, UK. The company specializes in creating advanced vaccines for viral respiratory diseases. In July 2025, Sanofi S.A. agreed to fully acquire ViceBio Limited from Medicxi Ventures, Avoro Capital Advisors, Goldman Sachs Asset Management, TCG Crossover Management, UniQuest Limited, and VenBio for USD 1.15 billion, plus an additional payment of up to USD 450 million based on development and regulatory achievements. The transaction is subject to customary closing conditions, including receipt of regulatory approvals. expected to close in Q4 2025.
ViceBio specializes in the development of next-generation vaccines targeting viral respiratory diseases, utilizing their innovative Molecular Clamp technology. This technology allows the creation of vaccines that provide broad protection against multiple pathogens and offers ready-to-use formulations that facilitate seamless manufacturability. Key products are aimed at addressing global health challenges related to respiratory diseases such as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). ViceBio's customer base includes healthcare providers, governmental health organizations, and pharmaceutical companies primarily in Europe, North America, and Australia. The vaccines are designed for diverse end users, particularly vulnerable populations including infants, the elderly, and individuals with compromised immune systems.
ViceBio generates revenue through strategic partnerships and collaborations with healthcare organizations and pharmaceutical companies. The revenue stream primarily consists of direct sales of innovative vaccine formulations structured as B2B agreements with health systems and distributors, enhanced by bulk purchasing contracts that facilitate access to their products for large healthcare providers. The revenue model benefits from ongoing clinical studies and advancements in their vaccine pipeline, setting the stage for future product launches and expanded market reach. Their products, especially those developed using the Molecular Clamp technology, are positioned to attract market interest upon release, which will contribute to the company’s financial performance.

## Funding rounds

- Series B, Sep 23, 2024, $100M — Goldman Sachs Asset Management, VenBio, UniQuest Limited, Medicxi, Avoro Capital Advisors, TCG Crossover Management

## Investors

- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- VenBio (https://capitalatlas.ai/funds/venbio) — Series B
- UniQuest Limited — Series B
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series B
- Avoro Capital Advisors — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B